Formation Bio

Formation Bio (formerly TrialSpark, founded 2016 in New York City) is a tech-driven, AI-native pharmaceutical company that aims to bring new treatments to patients faster and more efficiently. Rather than discovering drugs, Formation Bio in-licenses and acquires clinical-stage drug assets from pharma companies, universities, and biotech firms, then develops them using proprietary technology platforms, process automation, and large language models applied across the drug development lifecycle — patient recruitment, e-consent, data management, monitoring, and biostatistics. The company rebranded from TrialSpark to Formation Bio in 2023 as it moved from a pure clinical-trial software platform to combined platform-plus-asset ownership. It raised a $372M Series D in 2024 and announced a first-in-class AI collaboration with Sanofi and OpenAI. Formation Bio operates hybrid teams across New York City, Boston, the San Francisco Bay Area, and North Carolina's Research Triangle. It is a private company with no public developer API program; this profile captures its identity and public web surface for the API Evangelist network.

Formation Bio is profiled on the APIs.io network. Tagged areas include Company, Pharmaceutical, Biotechnology, Drug Development, and Clinical Trials.

Formation Bio’s developer surface includes engineering blog and 4 more developer resources.

🌐 Visit website 📡 Source on GitHub

11.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyPharmaceuticalBiotechnologyDrug DevelopmentClinical TrialsArtificial IntelligenceHealthcareLife Sciences

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 11.7/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.4 / 20

Commercial Clarity 2.1 / 20

Operational Transparency 0.7 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/formation-bio: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Build 1

SDKs, sample code, and the tooling you integrate with

GitHubOrganization

GitHubOrganization

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

Company 2

The organization behind the API

Website

Website

Blog

Blog

Source (apis.yml)

aid: formation-bio
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/formation-bio.png
name: Formation Bio
description: Formation Bio (formerly TrialSpark, founded 2016 in New York City) is a tech-driven, AI-native pharmaceutical
  company that aims to bring new treatments to patients faster and more efficiently. Rather than discovering drugs, Formation
  Bio in-licenses and acquires clinical-stage drug assets from pharma companies, universities, and biotech firms, then develops
  them using proprietary technology platforms, process automation, and large language models applied across the drug development
  lifecycle — patient recruitment, e-consent, data management, monitoring, and biostatistics. The company rebranded from TrialSpark
  to Formation Bio in 2023 as it moved from a pure clinical-trial software platform to combined platform-plus-asset ownership.
  It raised a $372M Series D in 2024 and announced a first-in-class AI collaboration with Sanofi and OpenAI. Formation Bio
  operates hybrid teams across New York City, Boston, the San Francisco Bay Area, and North Carolina's Research Triangle.
  It is a private company with no public developer API program; this profile captures its identity and public web surface
  for the API Evangelist network.
url: https://raw.githubusercontent.com/api-evangelist/formation-bio/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- a16z
- spark-capital
- sv-angel
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Pharmaceutical
- Biotechnology
- Drug Development
- Clinical Trials
- Artificial Intelligence
- Healthcare
- Life Sciences
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.formation.bio
- type: Blog
  url: https://www.formation.bio/blog
- type: PrivacyPolicy
  url: https://www.formation.bio/documents/privacy-policy
- type: GitHubOrganization
  url: https://github.com/trialspark
- type: DomainSecurity
  url: security/formation-bio-domain-security.yml
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence